AACE Vice President Daniel Einhorn, MD, FACP, FACE, also suggested a more aggressive approach to treating patients in high risk groups with medications, including Metformin, TZD's, DDP4 and GLP1.
"These medications illustrate a specific 'plan of attack' for treating prediabetes," Dr. Einhorn said. "But it's important that caution is exercised."
Prediabetes is a condition that leaves patients at risk for developing type 2 diabetes and cardiovascular complications. It is defined by elevated fasting glucose levels or impaired glucose tolerance, although Dr. Einhorn suggested A1c levels should be considered as a diagnostic tool.
"An A1c level of 6.0 to 6.5 indicates treatment for prediabetes with certain caveats," he said.
As with diabetes management, the new AACE recommendations focus on early detection and smart lifestyle choices.
"Lifestyle intervention should be the cornerstone of treatment for all patients," Einhorn said. "And it should be reinforced with each visit to the doctor."
A complete copy of the ACE/AACE Consensus Statement titled, "Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia - When do the Risks of Diabetes Begin?" is available for download on the AACE Web site here.
For more information about diabetes, download the American College of Endocrinology's (ACE) "Power of Prevention(R)" Magazine here. The magazine features medical information on prediabetes, type 1 and type 2 diabetes, diabetes complications, and tips on how diabetes patients can best prepare for disaster.
A short, one page bio and hig
|SOURCE American Association of Clinical Endocrinologists|
Copyright©2009 PR Newswire.
All rights reserved